Frequently Asked Questions (FAQ)
Why is the bone marrow microenvironment (niche) important for blood cancers and drug development?
The bone marrow is responsible for blood cell production and plays a critical role in hematopoietic stem cell maintenance and potency, immune regulation, and malignant cell behavior and disease progression. The surrounding niche strongly influences how cells respond to therapies, making it essential to study drugs within a relevant microenvironment.
What are Humaniche's bone marrow niche and patient/disease proxy platforms?
Humaniche develops in vitro/ex vivo bioengineered bone marrow microenvironments designed to integrate the key features of human bone marrow that regulate drug responses. Our platforms provide developers with human-, disease-, and patient-relevant niche environments for screening drug modalities before entering first-in-human trials or in parallel with clinical trials.
How can Humaniche improve drug development?
By more accurately representing human bone marrow and disease biology, Humaniche provides test platforms that help drug developers identify promising therapies earlier and eliminate ineffective or misleading candidates before costly clinical studies. The platforms support the evaluation of treatment efficacy, hematopoietic toxicity, resistance mechanisms, and patient- and cohort- specific responses, generating IND-enabling data and evidence more likely to translate into clinical outcomes.
This enables drug developers and researchers to:
Test therapies in patient-relevant in-vitro/ex-vivo models
Identify efficacy, toxicity, and resistance signals earlier
Improve confidence in candidate selection
De-risk clinical development and portfolio decisions
Support disease modelling and personalized medicine
Does the platform support New Approach Methodologies (NAMs)?
Yes. Humaniche's technology aligns with the growing adoption of New Approach Methodologies (NAMs), which aim to improve the relevance of preclinical testing through human-relevancy and defined context-of-use experimental systems.
How does Humaniche differ from existing preclinical culture platforms?
Conventional cultures fail to recapitulate the complex architecture and reciprocal cell-cell, cell-matrix, and soluble interstitial interactions that alter drug responses and treatment course. Humaniche recreates these critical features in controlled and reproducible model systems, enabling more physiologically relevant drug testing and mechanistic studies.
Unlike generic test and screening models, Humaniche is purpose-built for blood cancer and bone-marrow-related R&D. Its platforms combine patient-relevant marrow biology with advanced and combination therapy testing, long-term assessment, ease of use, and reproducible results for defined contexts of use that bridge preclinical research and clinical development.
Humaniche also offers a distinct customization and integration pathway, enabling its core technology to be tailored to specific customer requirements or integrated into existing preclinical platforms. See below for further details on our Customizable product line.
What applications can Humaniche models support?
Our technology can be used for:
Drug candidate screening, prioritization, and efficacy evaluation
Bone marrow and hematopoietic toxicity assessment
Translational validation using disease-specific and patient-derived samples
Evaluation of combination, cell, gene, and other advanced therapies
Mechanistic studies of treatment response, resistance, relapse, and disease progression
Preclinical and co-clinical research with defined patient cohorts for selected drug candidates
Patient-response modelling, precision medicine, and personalized therapy research
Disease modelling
Stem cell and hematopoiesis research
Can patient-derived samples or cells from existing biobanks be used?
Yes. Humaniche's models are designed to support the integration of both primary patient samples or cells from biobanks, enabling researchers to study disease-specific biology and therapeutic responses in a human-relevant environment.
Who can benefit from Humaniche's technology?
Pharmaceutical and biotechnology companies
Contract research organizations (CROs)
Contract development and manufacturing organizations (CD(R)MOs)*
Academic research institutions, translational research centers, and research clinics
How can I discuss a potential project with Humaniche?
We welcome collaborations with industry and academic partners. Contact our team to discuss your R&D objectives and explore how our models and platforms can support your programs.
Can existing model platforms/tools be used or adapted?
Yes. Humaniche’s "Customizable" product line is designed for integration into customer-defined or existing preclinical platforms. Together with licensing opportunities, it enables established tools to be adapted for bone-marrow-specific disease applications and strengthened with disease-relevant, human biological features.
*For potency validation of manufactured cell therapies
